NetworkNewsAudio Announces Audio Press Release (APR) the Advancement of First-in-Class Treatment for Multiple Sclerosis

About this update from Quantum Biopharma Ltd. Subordinate Voting Shares Class B

NetworkNewsAudio Announces Audio Press Release (APR) the Advancement of First-in-Class Treatment for Multiple Sclerosis AUSTIN, Texas, June 26, 2026 (GLOBE NEWSWIRE) -- via IBN – NetworkNewsAudio announces the Audio Press Release (APR) titled “Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis,” featuring Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM). To hear the NetworkNewsAudio version, visit https://ibn.fm/H77V1 To read the original editorial, visit: https://ibn.fm/wILk2 [Multiple sclerosis] carries a heavy economic burden as well. The global MS therapeutics market was valued at approximately $27.4 billion in 2024 and is forecast to reach $38.62 billion by 2030, driven not by cures but by the sheer number of patients requiring lifelong management. That market reality underscores the scale of the unmet need. Patients need more than management; they need a therapy that can interrupt the disease. That is precisely what Quantum BioPharma is working to deliver. The company is developing Lucid-MS, a patented, first-in-class drug candidate unlike anything currently approved, which targets the myelin sheath itself, with the goal of preventing, stopping and even possibly allowing for reversing its degradation. About Quantum BioPharma Ltd. Quantum is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum invented unbuzzd™ and spun out its OTC version to a company, Unbuzzd Wellness Inc. (“unbuzzd”) (formerly Celly Nutrition Corp.), led by industry veterans. Quantum retains ownership of 19.84% (as of March 31, 2026) of unbuzzd at www.unbuzzd.com. The agreement with unbuzzd also includes royalty payments of 7% of sales from unbuzzd™ until payments to Quantum total $250 million. Once $250 million is reached, the...

View stock analysis, news, and events for Quantum Biopharma Ltd. Subordinate Voting Shares Class B